Pragati Kumari and Ajay Valiyaveettil Salimkumar*

¹Bachelor of Fisheries Science, Kerala University of fisheries and Ocean Studies, Panangad, Kerala, India
²Department of Marine Environment and Resources, University of Bordeaux, France

*Corresponding Author: Ajay Valiyaveettil Salimkumar, Department of Marine Environment and Resources, University of Bordeaux, France.

Received: August 2, 2022; Published: August 23, 2022

Abstract

The human population currently suffers from a variety of metabolic illnesses, with type 2 diabetes(T2DM) and cardiovascular disease being the two most prevalent (CVD). These metabolic abnormalities affect both young and old persons, not just those who are elderly. Insufficient consumption of macronutrients, unhealthy lifestyle choices, and changes in the body's microbiota composition are typically the main causes of these illnesses. Changes in the microbiota's composition frequently cause obesity, metabolic endotoxemia, systemic inflammation, and beta cell dysfunction. The microbiota composition within the body can be considerably improved by biotherapeutics like probiotics and prebiotics, preventing type 2 diabetes (T2DM) and cardiovascular illnesses (CVD). They can also drastically cut cholesterol levels and enhance insulin levels in the body. Thus aids in reducing obesity. The present review deals with different types of metabolic disorders in human and how biotherapeutics can be used as an alternative way of treating them.

Keywords: Probiotics; Prebiotics; Cardiovascular Disease; Type 2 Diabetes; Obesity

References

1. Alokail MS., et al. “Effects of probiotics in patients with diabetes mellitus type 2: study protocol for a randomized, double-blind, placebo-controlled trial”. Trials1 (2013): 1-8.
2. Barna I., et al. “Review of the relation between gut microbiome, metabolic disease and hypertension”. Orvosi Hetilap9 (2018): 346-351.
3. Bordalo Tonucci L., et al. “Gut microbiota and probiotics: Focus on diabetes mellitus”. Critical Reviews in Food Science and Nutrition11 (2017): 2296-2309.
4. Borse SP., et al. “Probiotic use in the management of hypertension: A new era of therapeutic management”. Indian Journal of Health Sciences and Biomedical Research (KLEU)3 (2018): 207.
5. Chi C., et al. “Effects of probiotics on patients with hypertension: a systematic review and meta-analysis”. Current Hypertension Reports5 (2020): 1-8.
6. Chow J. “Probiotics and prebiotics: a brief overview”. Journal of Renal Nutrition2 (2002): 76-86.
7. Dallanora, et al. “Do probiotics effectively ameliorate glycemic control during gestational diabetes? A systematic review”. Archives of Gynaecology and Obstetrics298.3 (2018): 477-485.
8. Douglas LC and Sanders ME. “Probiotics and prebiotics in dietetics practice”. Journal of the American Dietetic Association 3 (2008): 510-521.
9. Dzherieva IS and Volkova NI. “Arterial hypertension and metabolic disorders”. Klinicheskaia Meditsina2 (2010): 4-8.
10. Esler M. “Sympathetic nervous system: contribution to human hypertension and related cardiovascular diseases”. Journal of Cardiovascular Pharmacology 26 (1995): S24-28.
11. Green M., et al. “Microbial medicine: prebiotic and probiotic functional foods to target obesity and metabolic syndrome”. International journal of molecular sciences8 (2020): 289.
12. Grundy SM. “Obesity, metabolic syndrome, and cardiovascular disease”. The Journal of Clinical Endocrinology and Metabolism6 (2004): 2595-2600.
13. Grundy SM. “Obesity, metabolic syndrome, and coronary atherosclerosis”. Circulation23 (2002): 2696-2698.
14. Grylls A., et al. “Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probiotics”. Biomedicine and Pharmacotherapy 137 (2021): 111334.
15. Ishimwe, et al. “The perspective on cholesterol‐lowering mechanisms of probiotics”. Molecular Nutrition and Food Research 59.1 (2015): 94-105.
16. Isolauri E., et al. “Microbial-gut interactions in health and disease Probiotics”. Best Practice and Research Clinical Gastroenterology2 (2004): 299-313.
17. Kang Y and Cai Y. “Gut microbiota and hypertension: From pathogenesis to new therapeutic strategies”. Clinics and Research in Hepatology and Gastroenterology2 (2018): 110-117.
18. Kannel WB and McGee DL. “Diabetes and cardiovascular risk factors: the Framingham study”. Circulation1 (1979): 8-13.
19. Koh KK., et al. “Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions”. Journal of the American College of Cardiology11 (2005): 1978-1985.
20. Kumar M., et al. “Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases”. Experimental Diabetes Research (2012).
21. Laaksonen DE., et al. “Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study”. American Journal of Epidemiology11 (2002): 1070-1077.
22. Lim S and Eckel RH. “Pharmacological treatment and therapeutic perspectives of metabolic syndrome”. Reviews in Endocrine and Metabolic Disorders4 (2014): 329-341.
23. Mallappa RH., et al. “Management of metabolic syndrome through probiotic and prebiotic interventions”. Endocrinology and Metabolism1 (2012): 20.
24. Miron IC., et al. “Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders”. Current Health Sciences Journal1 (2014): 12.
25. Nakamura YK and Omaye ST. “Metabolic diseases and pro-and prebiotics: mechanistic insights”. Nutrition and Metabolism 1 (2012): 1-9.
26. Ooi LG and Liong MT. “Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings”. International Journal of Molecular Sciences6 (2010): 2499-2522.
27. O’Connor, et al. “Prebiotics in the management of components of the metabolic syndrome”. Maturitas104 (2017): 11-18.
28. Pradhan A. “Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders”. Nutrition Reviews3 (2007): S152-S156.
29. Robles-Vera, et al. “Antihypertensive effects of probiotics”. Current Hypertension Reports19.4 (2017): 1-8.
30. Saito T and Shimazaki Y. “Metabolic disorders related to obesity and periodontal disease”. Periodontology 1 (2000): 254-266.
31. Sivamaruthi BS., et al. “A mini-review of human studies on cholesterol-lowering properties of probiotics”. Scientia Pharmaceutica4 (2019): 26.
32. Xavier-Santos D., et al. “Impact of probiotics and prebiotics targeting metabolic syndrome”. Journal of Functional Foods 64 (2020): 103-666.
33. Yasmin A., et al. “Prebiotics, gut microbiota and metabolic risks: Unveiling the relationship”. Journal of Functional Foods 17 (2015): 189-201.

Citation

Citation: Pragati Kumari and Ajay Valiyaveettil Salimkumar. “Biotherapeutics an Alternative Way of Treating Metabolic Disorders in Human. Category: Review Article". Acta Scientific Veterinary Sciences 4.9 (2022): 79-82.

Copyright

Copyright: © 2022 Pragati Kumari and Ajay Valiyaveettil Salimkumar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.